Sublimaze Overdose

Sublimaze is potent fentanyl-based narcotic. It’s administered via intravenous or intramuscular injection for anesthesia in surgery and for supportive post-operative pain relief. Sublimaze can only be administered by a certified anesthesiologist.

The amount of Sublimaze required to overdose is different for each patient. In general, smaller patients with a lower body fat percentage have a higher likelihood of experiencing complications from large doses.

Treatment for opioid overdose involves securing the patient’s airway, ensuring adequate respiration, and conducting life-saving procedures as needed. Patients who present with significant respiratory and circulatory depression may require an opioid antagonist to reverse the effects of the drug.

Symptoms of Sublimaze overdose include decreased level of consciousness, severe respiratory depression, and pinpointed pupils. These three symptoms are known as the “opioid overdose triad.”

Respiratory depression is the primary side effect of opioid overdose. Even at well-tolerated therapeutic doses, Sublimaze can induce significant respiratory depression. Doses must be titrated with care and patients monitored closely to ensure adequate respiration throughout the procedure.

Sublimaze inhibits the brain stem’s ability to regulate autonomic breathing. In the event of an overdose, the brain stem becomes unable to interpret electrical signals and to monitor for elevated carbon dioxide levels. The effect is that the patient’s body becomes unaware of the need to breathe.

When too much time elapses without adequate respiration and oxygenation, the cells can become starved of oxygen. This can lead to severe hypoxia (low oxygen). As hypoxia symptoms progress, the patient may present with severely dilated pupils. Earlier stages of overdose are characterized by pinpointed pupils that refuse to dilate even when exposed to total darkness.

If the patient is conscious during a Sublimaze overdose, they will experience a progressively decreasing level of consciousness. Individuals may deteriorate from fully alert and oriented to entirely unaware of their surroundings in a short time. Other signs of Sublimaze overdose include cold, clammy skin, blue lips and fingers, nausea, and vomiting.

The amount of Sublimize necessary to overdose varies dramatically among patients. Doses are administered intravenously in aqueous solution. 50 mcg of Sublimaze is contained in every one mL of fluid. Dosage is individualized to the unique metabolic factors of each patient. Factors that influence dose requirements include the patient’s weight, underlying medical conditions such as kidney and liver disease, age, overall physical health, the type of general anesthesia being used, route of administration, and the surgical procedure being conducted.

When Sublimaze is administered as a premedication to surgery, typical doses range from 50 mcg to 100 mcg. These are administered intramuscularly 30 to 60 minutes before surgery. Elderly patients or those who have already received depressant drugs may require a smaller dose. As an adjunct to regional anesthesia, doses of 50 mcg to 100 mcg may be administered intravenously over one to two minutes as additional pain relief is required. Usage in children can be as low as 2 to 3 mcg/kg.

Sublimaze overdose is managed first and foremost by re-establishing and protecting the patient’s airway. Supportive measures may include the institution of controlled ventilation through the placement of an intubation tube. If respiratory deterioration is less severe, ventilations may be assisted via a manually-operated bag-valve mask.

Other supportive measures such as oxygen therapy and vasopressors may be required. Circulatory shock and pulmonary edema are additional risk factors associated with Sublimaze overdose. Advanced life-support procedures including CPR and shock treatment will be required in the event of cardiac arrest or heart arrhythmias.

Administration of an opioid antagonist may be required if the patient presents with clinically significant circulatory or respiratory depression. An opioid antagonist should not be administered without the presence of severe respiratory depression as this could lead to the development of further complications. Naloxone and nalmefene are common opioid antagonists, although naloxone tends to be used in most circumstances.

Naloxone reverses the effects of opioids like Sublimaze by disrupting the bonds formed between the drug and opioid receptor sites in the body. The duration of opioid reversal can vary between patients. Individuals should be carefully monitored following administration of naloxone for returning symptoms of respiratory depression. If a single dose of naloxone proves insufficient to correct respiratory depression, additional doses may be administered. Opioid antagonists can precipitate the onset of severe post-acute withdrawal symptoms in opioid-dependent patients.

Medical Disclaimer: The Recovery Village aims to improve the quality of life for people struggling with a substance use or mental health disorder with fact-based content about the nature of behavioral health conditions, treatment options and their related outcomes. We publish material that is researched, cited, edited and reviewed by licensed medical professionals. The information we provide is not intended to be a substitute for professional medical advice, diagnosis or treatment. It should not be used in place of the advice of your physician or other qualified healthcare provider.